Log In
BCIQ
Print this Print this
 

biosimilar omalizumab (FB317)

  Manage Alerts
Collapse Summary General Information
Company Fountain Biopharma Inc.
DescriptionBiosimilar of Xolair omalizumab
Molecular Target
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAsthma
Indication DetailsTreat severe asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today